MXPA04001240A - Analogos antitumorales. - Google Patents

Analogos antitumorales.

Info

Publication number
MXPA04001240A
MXPA04001240A MXPA04001240A MXPA04001240A MXPA04001240A MX PA04001240 A MXPA04001240 A MX PA04001240A MX PA04001240 A MXPA04001240 A MX PA04001240A MX PA04001240 A MXPA04001240 A MX PA04001240A MX PA04001240 A MXPA04001240 A MX PA04001240A
Authority
MX
Mexico
Prior art keywords
substituted
unsubstituted
independently selected
alkynyl
alkenyl
Prior art date
Application number
MXPA04001240A
Other languages
English (en)
Inventor
Manzanares Ignacio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MXPA04001240A publication Critical patent/MXPA04001240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivados de ecteinascidina 736 de la formula general (I): en la que cada uno de los grupos R1, R2, R3, R4 y R5 esta seleccionado independientemente del grupo que consiste de H, OH, OR, SH, SR', SOR', SO2R', C(=O)R', C(=O)OR', NO2, NH2, NHR', N(R')2, NHC(O)R', CN, halogeno, =O, alquilo sustituido o no sustituido de 1 a 25 atomos de carbono, alquinilo sustituido o no sustituido, de 2 a 18 atomos de carbono, alquinilo sustituido o no sustituido, de 2 a 18 atomos de carbono, arilo sustituido o no sustituido, heterociclico sustituido o no sustituido; donde X esta seleccionado independientemente de OR', CN, (=O) o H; donde cada uno de los grupos R' esta seleccionado independientemente del grupo que consiste de H, OH, NO2, NH2, SH, CN, halogeno, =O, C(=O)H, C(=O)CH3, CO2H, alquilo sustituido o no sustituido, de 1 a 25 atomos de carbono, alquenilo sustituido o no sustituido, de 2 a 18 atomos de carbono, alquinilo sustituido o no sustituido de 2 a 18 atomos de carbono, arilo sustituido o no sustituido; donde m es 0, 1 o 2; y donde n es 0, 1, 2, 3 o 4; y su uso como agente antitumoral.
MXPA04001240A 2001-08-07 2002-08-06 Analogos antitumorales. MXPA04001240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743
PCT/GB2002/003592 WO2003014127A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs

Publications (1)

Publication Number Publication Date
MXPA04001240A true MXPA04001240A (es) 2004-06-03

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001240A MXPA04001240A (es) 2001-08-07 2002-08-06 Analogos antitumorales.

Country Status (23)

Country Link
US (1) US7763615B2 (es)
EP (3) EP1806349A1 (es)
JP (2) JP4684552B2 (es)
KR (1) KR20040032150A (es)
CN (1) CN100334094C (es)
AT (1) ATE374777T1 (es)
AU (1) AU2002313540B2 (es)
CA (1) CA2455768C (es)
CY (1) CY1107830T1 (es)
DE (1) DE60222775T2 (es)
DK (1) DK1414828T3 (es)
ES (1) ES2294151T3 (es)
GB (1) GB0119243D0 (es)
HK (1) HK1065786A1 (es)
HU (1) HU229779B1 (es)
IL (2) IL160051A0 (es)
MX (1) MXPA04001240A (es)
NO (1) NO337476B1 (es)
NZ (1) NZ530837A (es)
PL (1) PL218295B1 (es)
PT (1) PT1414828E (es)
RU (1) RU2283842C2 (es)
WO (1) WO2003014127A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
AU2009204048B2 (en) * 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
JP6037337B2 (ja) * 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
ES2688086T3 (es) 2010-11-26 2018-10-30 Nec Corporation Dispositivo de descodificación de video, método de descodificación de video y programa
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
BR112022003149A2 (pt) 2019-09-03 2022-05-17 Pharma Mar Sa Lurbinectedina no tratamento de mesotelioma maligno
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
CN115151259A (zh) * 2019-11-21 2022-10-04 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
EP4138923A1 (en) 2020-04-21 2023-03-01 Pharma Mar, S.A. Drug antibody conjugates
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
JP2023541010A (ja) 2020-09-04 2023-09-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジンと免疫チェックポイント阻害剤との組合せ
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
CA3229559A1 (en) * 2021-08-31 2023-03-09 Srinivasa Chary CHINTALAPATI Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin
WO2023079177A1 (en) 2021-11-08 2023-05-11 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
CN100548988C (zh) 1998-05-11 2009-10-14 法马马有限公司 海鞘素743的代谢物
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
NO337476B1 (no) 2016-04-18
NO20040961L (no) 2004-03-05
CA2455768C (en) 2011-10-11
CN1564822A (zh) 2005-01-12
US20060128711A1 (en) 2006-06-15
ES2294151T3 (es) 2008-04-01
HU229779B1 (en) 2014-07-28
CY1107830T1 (el) 2013-06-19
DE60222775D1 (de) 2007-11-15
IL160051A0 (en) 2004-06-20
US7763615B2 (en) 2010-07-27
JP2005501093A (ja) 2005-01-13
JP2011026331A (ja) 2011-02-10
HK1065786A1 (en) 2005-03-04
EP1414828A1 (en) 2004-05-06
EP1414828B9 (en) 2008-02-20
HUP0401174A3 (en) 2005-12-28
EP1806349A1 (en) 2007-07-11
GB0119243D0 (en) 2001-10-03
CA2455768A1 (en) 2003-02-20
PL367940A1 (en) 2005-03-07
PT1414828E (pt) 2007-12-27
NZ530837A (en) 2005-07-29
RU2283842C2 (ru) 2006-09-20
AU2002313540B2 (en) 2008-05-22
KR20040032150A (ko) 2004-04-14
IL160051A (en) 2012-01-31
CN100334094C (zh) 2007-08-29
DK1414828T3 (da) 2008-02-04
EP1414828B1 (en) 2007-10-03
ATE374777T1 (de) 2007-10-15
DE60222775T2 (de) 2008-07-17
EP2270018A1 (en) 2011-01-05
RU2004106617A (ru) 2005-04-10
HUP0401174A2 (hu) 2005-09-28
WO2003014127A1 (en) 2003-02-20
JP4684552B2 (ja) 2011-05-18
PL218295B1 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
MXPA04001240A (es) Analogos antitumorales.
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
ATE356117T1 (de) Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
HK1039727A1 (en) Synthetic analogs of ecteinascidin-743
TW200503993A (en) Arylalkylcarbamate derivatives, their preparation and their application in therapy
CY1113359T1 (el) Αντι-νεοπλασιακα παραγωγα του et-743
HUP0104033A2 (hu) Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
PT1468692E (pt) Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
HK1060354A1 (en) Variolin derivatives and their use as antitumor agents
AU3387301A (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
HUP0402149A2 (hu) Vízoldható fenil-piridazin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
TH58475B (th) อนุพันธุ์ของ 1,4-ไดอะซาไบไซโคล [3.2.2]โนเนน-4-คาร์บอกซีเลต และ คาร์บอกซามีด การเตรียมและการใช้รักษาโรค

Legal Events

Date Code Title Description
FG Grant or registration